deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT01459484

ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma (ISG/OS-2)

ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma - Prospective Study (ISG/OS-2)

Sponsor: Italian Sarcoma Group

Conditions Osteosarcoma
Interventions 3 drugs arm Mifamurtide arm
Updated 15 times since 2017 Last updated: May 17, 2024 Started: Jun 23, 2011 Primary completion: Apr 30, 2024 Completion: Apr 30, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01459484, this PHASE2 trial focuses on Osteosarcoma and remains completed. Sponsored by Italian Sarcoma Group, it has been updated 15 times since 2011, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Feb 2020 · 7 months · monthly snapshot~Feb 2020 – ~May 2020 · 3 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Nov 2023 · 14 months · monthly snapshot~Nov 2023 – ~Jun 2024 · 7 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Nov 2023 — Jun 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 10 earlier versions

  1. Sep 2022 — Nov 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

    Phase: PHASE2_PHASE3 → PHASE2

  3. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  4. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  5. May 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  6. Feb 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  7. Jul 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Completed → Active Not Recruiting

  8. Jun 2019 — Jul 2019 [monthly]

    Completed PHASE2_PHASE3

    Status: Recruiting → Completed

  9. Jun 2018 — Jun 2019 [monthly]

    Recruiting PHASE2_PHASE3

  10. Jan 2017 — Jun 2018 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Italian Sarcoma Group
Data source: Italian Sarcoma Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations